Rydex Biotechnology Fund Class A (RYBOX)

Fund Assets	123.77M
Expense Ratio	1.65%
Min. Investment	$2,500
Turnover	75.00%
Dividend (ttm)	n/a
Dividend Yield	n/a
Dividend Growth	n/a
Payout Frequency	n/a
Ex-Dividend Date	Dec 16, 2025

Previous Close	81.01
YTD Return	30.64%
1-Year Return	60.15%
5-Year Return	42.72%
52-Week Low	58.62
52-Week High	81.29
Beta (5Y)	0.88
Holdings	73
Inception Date	Sep 1, 2004

About RYBOX

Rydex Biotechnology Fund Class A is a mutual fund designed to provide investors with targeted exposure to the biotechnology sector. Its primary purpose is capital appreciation by investing at least 80% of its net assets in equity securities of biotechnology companies, including firms engaged in research, development, manufacturing, and marketing of products and services based on advanced biological processes. The fund is team-managed and seeks to minimize single stock risk through diversified holdings across industry leaders and emerging innovators. Notable portfolio positions include prominent biotechnology companies such as Gilead Sciences, Regeneron Pharmaceuticals, and Alnylam Pharmaceuticals. By focusing on this sector, the fund plays a significant role for investors seeking access to the growth potential and scientific advancements within biotechnology—an industry that impacts healthcare, pharmaceuticals, agriculture, and related fields. The fund’s structure, with a relatively high expense ratio and an annual distribution schedule, caters to investors who are interested in specialized sector exposure rather than broad market diversification.

• Fund Family: Rydex Funds
• Category: Health
• Performance Rating: Above Average
• Risk Rating: Average
• Stock Exchange: NASDAQ
• Ticker Symbol: RYBOX
• Share Class: Class A
• Index: S&P 500 TR

Performance

RYBOX had a total return of 60.15% in the past year, including dividends. Since the fund's inception, the average annual return has been 11.58%.

Equivalent Funds

These are funds that follow the same index from the other major fund companies.

Symbol	Provider	Name	Expense Ratio
FIKCX	Fidelity	Fidelity Advisor Health Care Z	0.56%
FSPHX	Fidelity	Fidelity Select Health Care Portfolio	0.62%
FIJYX	Fidelity	Fidelity Advisor Biotechnology Z	0.58%
FSHCX	Fidelity	Fidelity Select Health Care Services Portfolio	0.67%
FBTAX	Fidelity	Fidelity Advisor Biotechnology A	0.96%

Other Share Classes

These are alternative share classes of the same fund, from the same provider.

Symbol	Share Class	Expense Ratio
RYOIX	Investor Class	1.40%
RYOAX	Class H	1.65%
RYCFX	Class C	2.40%

Top 10 Holdings

36.17% of assets

Name	Symbol	Weight
AbbVie Inc.	ABBV	8.15%
Amgen Inc.	AMGN	5.04%
Gilead Sciences, Inc.	GILD	4.48%
Vertex Pharmaceuticals Incorporated	VRTX	4.31%
Regeneron Pharmaceuticals, Inc.	REGN	2.93%
Revolution Medicines, Inc.	RVMD	2.47%
Alnylam Pharmaceuticals, Inc.	ALNY	2.35%
BeOne Medicines AG	ONC	2.17%
Moderna, Inc.	MRNA	2.14%
Biogen Inc.	BIIB	2.12%

Dividend History

Ex-Dividend	Amount	Pay Date
Dec 16, 2025	$9.40578	Dec 16, 2025
Dec 12, 2024	$9.42277	Dec 12, 2024
Dec 20, 2022	$0.89943	Dec 20, 2022
Dec 8, 2021	$15.77303	Dec 8, 2021
Dec 9, 2020	$6.95038	Dec 9, 2020
Dec 10, 2019	$3.60206	Dec 10, 2019

Data Sources: Tiingo, Twelve Data, and more

Historical data is provided by Tiingo. Delayed stock pricing data is provided by Twelve Data. Several fund data points are also provided by Finnhub.

Last checked:

Aug 28, 2026

Data Sources Report a data error